【摘要】 TRIPS协定第39.3条的规定让不同国家面临着不同的药品试验数据保护模式的选择。面对发达国家通过FTAs推行药品试验数据独占保护制度的强大攻势,以及独占保护模式可以带来的积极效果,发展中国家固守原有的反不正当竞争模式的做法,并不利于与发达国家在FTAs中的博弈,也不利于自身的长远利益。在此背景下,建构一个有别于发达国家的、符合自身利益的、能够保障公共健康的药品试验数据独占保护制度可能才是发展中国家的最佳选择。更多还原

【Abstract】 Article 39.3 of TRIPS agreement makes different countries face different options of pharmaceutical test data protection modes. Faced with the powerful offensive of the developed countries for exclusive protection system of pharmaceutical test data through FTAs, and the positive effect brought by the exclusive protection mode, the developing countries’ practice of sticking to their original model of anti-unfair competition is not conducive to their game with the developed countries in the FTAs, as well as their long-term interests. In this context, to construct an exclusive protection system of pharmaceutical test data which is different from the one of developed countries’, in line with their own interests and which can safeguard public healthy may be the best choice for the developing countries.更多还原